Peer-Reviewed Publication
Dig Dis Sci2026September 8, 2026Journal Article
Statin Continuation After an Index Hospitalization for Hepatic Decompensation in MASLD Cirrhosis.
Mohammad Alabbas1,2, Akram Alnounou3, EzzElDien A Ibrahim4, Abdulrahman M Karam5, Barbara Balog6, Bisher Sawaf5, Basile Njei7
1Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic Foundation, Cleveland, OH, USA. alabbam@ccf.org.
2Division of Gastroenterology and Hepatology, NewYork-Presbyterian Hospital/Weill Cornell Medicine, New York, NY, USA. alabbam@ccf.org.
3Department of Internal Medicine, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, MI, USA.
4Department of Medicine, University of Missouri-Columbia, Columbia, MO, USA.
5Department of Internal Medicine, The University of Toledo, Toledo, OH, USA.
6Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Nagyerdei Krt. 98, 4032, Debrecen, Hungary.
7Section of Digestive Diseases, Yale School of Medicine, New Haven, CT, USA.
Abstract
BACKGROUND: Whether established statin therapy should be continued after hospitalization for hepatic decompensation in metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis remains uncertain.
METHODS: We performed a retrospective multicenter cohort study in the TriNetX Research network. Adults aged 18-75 years with MASLD cirrhosis, a qualifying inpatient decompensation event,…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans